Meta‐analysis results do not reflect the real safety of biologics in psoriasis*

Archive ouverte

Afach, S. | Chaimani, A. | Evrenoglou, Theodoros | Le Cleach, L. | Penso, L. | Brouste, E. | Sbidian, E.

Edité par CCSD ; Wiley -

International audience. In reported systematic reviews and meta-analyses of randomized controlled trials (RCTs) assessing treatments for psoriasis, the proportion of serious adverse events (SAEs) did not differ between treatments and placebo. Including cases of psoriasis worsening as SAEs may explain the lack of difference.

Consulter en ligne

Suggestions

Du même auteur

Drop in biological initiation for patients with psoriasis during the COVID‐19 pandemic

Archive ouverte | Penso, L. | CCSD

International audience

Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments

Archive ouverte | Obeid, G. | CCSD

International audience

Individual‐ and hospital‐level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012–2016

Archive ouverte | Traikia, C. | CCSD

International audience

Chargement des enrichissements...